News
Read all about our latest news.
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
Contact Us
We believe that neuroscience will be in the next decade what oncology has been in the last.
